XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Change in Accounting Estimate [Line Items]          
Capital resources $ 182,100   $ 182,100    
Net loss 114,506 $ 43,173 93,373 $ 87,150  
Accumulated deficit 1,241,918   1,241,918   $ 1,148,545
Letter of credit established as a deposit $ 1,500   1,500    
Kite Pharma, Inc.          
Change in Accounting Estimate [Line Items]          
Increase in revenue     8,900    
Increase in net income     $ 8,900    
Increased earnings per share, basic (in dollars per share)     $ 0.06    
Increased earnings per share, diluted (in dollars per share)     $ 0.06